Abstract
Osteoporosis, a condition that is described by a decrease in bone mass, is further defined by the WHO as a bone mineral density (BMD) that is 2.5 standard deviations less than that of a young and healthy group of people. This is typically measured using a dual energy X-ray absorptiometry or (DXA) and is expressed as a T-score wherein a score of less than −2.5 is defined as osteoporosis and a score between −1 and −2.5 is defined as osteopenia. The T-score is a measure of standard deviation compared to young, healthy sex-matched controls. A Z-score, on the other hand, is a standard deviation measurement with age- and sex-matched controls as a point of comparison. Osteoporosis can further be diagnosed clinically in the presence of an osteoporotic fracture. Chronic obstructive pulmonary disease has been widely studied as a risk factor for the development of osteoporosis in both males and females and several mechanisms that address them have been suggested and investigated. Awareness of this relationship should prompt osteoporosis-screening initiatives for COPD patients and lead to early recognition and treatment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
WHO Study Group on Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Assessment of fracture risk and its application to screening for postmenopausal osteoprorosis: A Report of a WHO Study Group. Geneva 1994.
Cazzola M, Bettoncelli G, Sessa E, Cricelli C, Biscione G. Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration. 2010;80(2):112–9.
Jørgensen NR, Schwarz P, Holme I, Henriksen BM, Petersen LJ, Backer V. The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. Respir Med. 2007;101(1):177–85.
Vrieze A et al. Low bone mineral density in COPD patients related to worse lung function, low weight and decreased fat = free mass. Osteoporos Int. 2007;18:1197–202.
Nuti R, Siviero P, Maggi S, Guglielmi G, Caffarelli C, Crepaldi G, et al. Vertebral fractures in patients with chronic obstructive pulmonary disease: the EOLO Study. Osteoporos Int. 2009;20(6):989–98.
Biskobing DM. COPD and osteoporosis. Chest. 2002;121(2):609–20.
Selemenda CW et al. Long term bone loss in men: effects of genetic and environmental factors. Ann Intern Med. 1992;117:286–91.
Ionescu AA, Schoon E. Osteoporosis in Chronic obstructive pulmonary disease. Eur Respir J. 2003;22 Suppl 46:64s–75.
Schols AM, Wouters EF. Nutritional abnormalities and supplementation in chronic obstructive pulmonary disease. Clin Chest Med. 2000;21:753–62.
Incalzi RA, Caradonna P, Ranieri P, et al. Correlates of osteoporosis in chronic obstructive pulmonary disease. Respir Med. 2000;94:1079–84.
Langhammer A, Forsmo S, Syversen U. Long-term therapy in COPD: any evidence of adverse effect on bone? Int J COPD. 2009;4:365–80.
Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med. 1991;114:919–23.
Carter JD, Patel S, Sultan FL, Thompson ZJ, Margaux H, Sterrett A, et al. The recognition and treatment of vertebral fractures in males with chronic obstructive pulmonary disease. Respir Med. 2008;102:1165–72.
Marshall D, Johnell O, Wedel H. Meta-analyses of how well measures of bone mineral density predict the occurrence of osteoporotic fractures. BMJ. 1996;312:1254–9.
Kanis JA, Melton III LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137–41.
Janssens W, Lehouck A, Carremans C, Bouillon R, Mathieu C, Decramer M. Vitamin D beyond bones in chronic obstructive pulmonary disease time to act. Am J Respir Crit Care Med. 2009;179:630–6.
Adachi JD. Corticosteroid-induced osteoporosis. Am J Med Sci. 1997;313:41–9.
Doerr P, Pirke KM. Cortisol-induced suppression of plasma testosterone in normal adult males. J Clin Endocrinol Metab. 1976;43:622–8.
Bourjeily G, Rochester CL. Exercise training in chronic obstructive pulmonary disease. Clin Chest Med. 2000;21:763–81.
Cooper C, Barker DJ, Wickham C. Physical activity, muscle strength and calcium intake in fractures of the proximal femur in Britain. BMJ. 1988;297:1443–6.
Gregg EW, Cauley JA, Seeley DG, et al. Physical activity and osteoporotic fracture risk in older women. Ann Intern Med. 1998;129:81–8.
Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532–55.
National Osteoporosis Foundation. NOF physician’s guidelines; September 2005. Pharmacologic options. http://www.nof.org/professionals/clinical.htm. Accessed 20 June 2007.
US Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med. 2002;137:526–8.
Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18(10):1319–28.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Diez-Morales, L.F., Cunanan, V. (2012). Osteoporosis. In: Nici, L., ZuWallack, R. (eds) Chronic Obstructive Pulmonary Disease. Respiratory Medicine. Humana Press. https://doi.org/10.1007/978-1-60761-673-3_5
Download citation
DOI: https://doi.org/10.1007/978-1-60761-673-3_5
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-672-6
Online ISBN: 978-1-60761-673-3
eBook Packages: MedicineMedicine (R0)